Abstract

Neuropeptide Y (NPY) produces anxiolytic effects in rodent models, and naturally occurring low NPY expression in humans has been associated with negative emotional phenotypes. Studies in rodent models have also demonstrated that NPY elicits reward behaviors through its action in the nucleus accumbens (NAc), but the impact of NPY on the human NAc is largely unexplored. We recruited 222 healthy young adults of either sex and genetically selected 53 of these subjects at the extremes of NPY expression (Low-NPY and High-NPY) to participate in functional magnetic resonance imaging. Responses of the NAc and surrounding ventral striatum were quantified during a monetary incentive delay task in which stimuli varied by salience (high versus low) and valence (win versus loss). We found that bilateral NAc responses to high-salience versus low-salience stimuli were greater for Low-NPY subjects relative to High-NPY subjects, regardless of stimulus valence. To our knowledge, these results provide the first evidence in humans linking NPY with salience sensitivity of the NAc, raising the possibility that individual differences in NPY expression moderate the risk for disorders of mesoaccumbal function such as addictions and mood disorders. Additionally, we found that head motion was greater among High-NPY subjects, consistent with previous reports linking NPY with hyperactivity. Future studies in animal models are warranted to elucidate the neural mechanisms through which NPY influences NAc function and related behaviors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossor MN, Roberts GW, et al. Neuropeptide Y distribution in human brain. Nature. 1983;306:584–6.

  2. 2.

    Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, et al. Neuropeptide Y distribution in the rat brain. Science. 1983;221:877–9.

  3. 3.

    Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296:659–60.

  4. 4.

    Kask A, Harro J, Hörsten S, von, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev. 2002;26:259–83.

  5. 5.

    Reichmann F, Holzer P. Neuropeptide Y: a stressful review. Neuropeptides. 2016;55:99–109.

  6. 6.

    Josselyn SA, Beninger RJ. Neuropeptide Y: intraaccumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol Biochem Behav. 1993;46:543–52.

  7. 7.

    Brown CM, Coscina DV, Fletcher PJ. The rewarding properties of neuropeptide Y in perifornical hypothalamus vs. nucleus accumbens. Peptides. 2000;21:1279–87.

  8. 8.

    Borkar CD, Upadhya MA, Shelkar GP, Subhedar NK, Kokare DM. Neuropeptide Y system in accumbens shell mediates ethanol self-administration in posterior ventral tegmental area. Addict Biol. 2016;21:766–75.

  9. 9.

    Adewale AS, Macarthur H, Westfall TC. Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007;52:1396–402.

  10. 10.

    Quarta D, Leslie CPP, Carletti R, Valerio E, Caberlotto L. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology. 2011;60:328–35.

  11. 11.

    Ault DT, Werling LL. Differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and σ receptor ligands. Brain Res. 1997;760:210–7.

  12. 12.

    Van Den Heuvel JK, Furman K, Gumbs MCRR, Eggels L, Opland DM, Land BB, et al. Neuropeptide Y activity in the nucleus accumbens modulates feeding behavior and neuronal activity. Biol Psychiatry. 2015;77:633–41.

  13. 13.

    Tepper JM, Tecuapetla F, Koós T, Ibáñez-Sandoval O, Lanciego JL, Bracci E, et al. Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat. 2010;4:1–18.

  14. 14.

    Morgan CA, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry. 2002;52:136–42.

  15. 15.

    Yehuda R, Brand S, Yang R-K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry. 2006;59:660–3.

  16. 16.

    Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjögren M, et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res. 2004;38:113–21.

  17. 17.

    Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem. 1992;59:73–80.

  18. 18.

    Widerlöv E, Lindström LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res. 1988;22:69–79.

  19. 19.

    Zhou Z, Zhu G, Hariri AR, Enoch M-A, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452:997–1001.

  20. 20.

    Mickey BJ, Zhou Z, Heitzeg MM, Heinz E, Hodgkinson CA, Hsu DT, et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry. 2011;68:158.

  21. 21.

    Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391–9.

  22. 22.

    Carlezon WAJ, Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology. 2009;56:122–32.

  23. 23.

    Berridge KC. Motivation concepts in behavioral neuroscience. Physiol Behav. 2004;81:179–209.

  24. 24.

    Namburi P, Al-Hasani R, Calhoon GG, Bruchas MR, Tye KM. Architectural representation of valence in the limbic system. Neuropsychopharmacology. 2016;41:1697–715.

  25. 25.

    Volman SF, Lammel S, Margolis EB, Kim Y, Richard JM, Roitman MF, et al. New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. J Neurosci. 2013;33:17569–76.

  26. 26.

    Berridge KC, Kringelbach ML. Pleasure systems in the brain. Neuron. 2015;86:646–64.

  27. 27.

    Ibáñez-Sandoval O, Tecuapetla F, Unal B, Shah F, Koós T, Tepper JM. A novel functionally distinct subtype of striatal neuropeptide Y interneuron. J Neurosci. 2011;31:16757–69.

  28. 28.

    Cooper JC, Knutson B. Valence and salience contribute to nucleus accumbens activation. Neuroimage. 2008;39:538–47.

  29. 29.

    Field AS, Yen YF, Burdette JH, Elster AD. False cerebral activation on BOLD functional MR images: study of low-amplitude motion weakly correlated to stimulus. AJNR Am J Neuroradiol. 2000;21:1388–96.

  30. 30.

    Hajnal JV, Myers R, Oatridge A, Schwieso JE, Young IR, Bydder GM. Artifacts due to stimulus correlated motion in functional imaging of the brain. Magn Reson Med. 1994;31:283–91.

  31. 31.

    Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE, Barnes KA. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage Neuroimage Febr. 2012;1:2142–54.

  32. 32.

    Sacchet MD, Knutson B. Spatial smoothing systematically biases the localization of reward-related brain activity. Neuroimage. 2013;66:270–7.

  33. 33.

    Mickey BJ, Heffernan J, Heisel C, Peciña M, Hsu DT, Zubieta J-K, et al. Oxytocin modulates hemodynamic responses to monetary incentives in humans. Psychopharmacology. 2016;233:3905–19.

  34. 34.

    Lesch K-P, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T, et al. Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry. 2010;16:491–503.

  35. 35.

    Domschke K, Dannlowski U, Hohoff C, Ohrmann P, Bauer J, Kugel H, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol. 2010;20:301–9.

  36. 36.

    Dumont Y, Quirion R. Neuropeptide Y pathways in anxiety-related disorders. Biol Psychiatry. 2014;76:834–5.

  37. 37.

    Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem. 2007;7:1645–59.

  38. 38.

    Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38:213–24.

  39. 39.

    Heilig M, Thorsell A. Brain neuropeptide Y (NPY) in stress and alcohol dependence. Rev Neurosci. 2002;13:85–94.

  40. 40.

    Karl T, Herzog H. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides. 2007;28:326–33.

  41. 41.

    Roitman MF, Wheeler RA, Carelli RM. Nucleus accumbens neurons are innately tuned for rewarding and aversive taste stimuli, encode their predictors, and are linked to motor output. Neuron. 2005;45:587–97.

  42. 42.

    Partridge JG, Janssen MJ, Chou DYT, Abe K, Zukowska Z, Vicini S. Excitatory and inhibitory synapses in neuropeptide Y–expressing striatal interneurons. J Neurophysiol. 2009;105:3038–45.

  43. 43.

    Logothetis NK. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. R Soc. 2002;357:1003–37.

  44. 44.

    Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature. 2001;412:150–7.

  45. 45.

    Floresco SB. The nucleus accumbens: an interface between cognition, emotion, and action. Annu Rev Psychol. 2015;66:25–52.

  46. 46.

    Keller J, Young CB, Kelley E, Prater K, Levitin DJ, Menon V. Trait anhedonia is associated with reduced reactivity and connectivity of mesolimbic and paralimbic reward pathways. J Psychiatr Res. 2013;47:1319–28.

  47. 47.

    Zhang B, Lin P, Shi H, Öngür D, Auerbach RP, Wang X, et al. Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis. Brain Imaging Behav. 2016;10:920–39.

  48. 48.

    Admon R, Holsen LM, Aizley H, Remington A, Whitfield-Gabrieli S, Goldstein JM, et al. Striatal hyper-sensitivity during stress in remitted individuals with recurrent depression. Biol Psychiatry. 2015;78:67–76.

Download references

Acknowledgements

We thank Yarden Ginsburg and staff at the Michigan Clinical Research Unit for help with clinical assessment and phlebotomy; Bob Lyons and the UM DNA Sequencing Core for sequencing; Tom Chenevert, Suzan Lowe, and Sara Easler in the UM Department of Radiology for assistance with fMRI acquisition; Shana Black, Joe Heffernan, and Daniel Kessler for fMRI processing tools; and Brian Knutson for helpful discussions. This study was supported by NIMH (K23 MH092648), NCRR (UL1 RR024986), NCATS (2UL1 TR000433). Dr. Mickey reports no biomedical financial interests related to this work over the last 3 years or in the foreseeable future. In 2016, he served as a paid consultant to Alkermes, Inc., on an unrelated topic.

Author information

Affiliations

  1. University of Utah, Salt Lake City, UT, 84108, USA

    • Katherine G. Warthen
    • , Keith G. Jones
    • , Jon-Kar Zubieta
    • , Robert C. Welsh
    •  & Brian J. Mickey
  2. University of Michigan, Ann Arbor, MI, 48109, USA

    • Benjamin Sanford
    • , Kendal Walker
    • , Mike Angstadt
    • , Chandra Sripada
    • , Jon-Kar Zubieta
    • , Margit Burmeister
    •  & Brian J. Mickey
  3. NIAAA, Rockville, MD, 20852, USA

    • David Goldman

Authors

  1. Search for Katherine G. Warthen in:

  2. Search for Benjamin Sanford in:

  3. Search for Kendal Walker in:

  4. Search for Keith G. Jones in:

  5. Search for Mike Angstadt in:

  6. Search for Chandra Sripada in:

  7. Search for David Goldman in:

  8. Search for Jon-Kar Zubieta in:

  9. Search for Robert C. Welsh in:

  10. Search for Margit Burmeister in:

  11. Search for Brian J. Mickey in:

Competing interests

The authors declare no competing interestst.

Corresponding author

Correspondence to Brian J. Mickey.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41386-018-0230-6